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Abstract
We recently reported that HIV-1 infection can be inhibited by innate antimicrobial components of human seminal plasma
(SP). Conversely, naturally occurring peptidic fragments from the SP-derived prostatic acid phosphatase (PAP) have been
reported to form amyloid fibrils called ‘‘SEVI’’ and enhance HIV-1 infection in vitro. In order to understand the biological
consequence of this proviral effect, we extended these studies in the presence of human SP. PAP-derived peptides were
agitated to form SEVI and incubated in the presence or absence of SP. While PAP-derived peptides and SEVI alone were
proviral, the presence of 1% SP ablated their proviral activity in several different anti-HIV-1 assays. The anti-HIV-1 activity of
SP was concentration dependent and was reduced following filtration. Supraphysiological concentrations of PAP peptides
and SEVI incubated with diluted SP were degraded within hours, with SP exhibiting proteolytic activity at dilutions as high
as 1:200. Sub-physiological concentrations of two prominent proteases of SP, prostate-specific antigen (PSA) and
matriptase, could degrade physiological and supraphysiological concentrations of PAP peptides and SEVI. While human SP
is a complex biological fluid, containing both antiviral and proviral factors, our results suggest that PAP peptides and SEVI
may be subject to naturally occurring proteolytic components capable of reducing their proviral activity.
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Introduction
Mucosal tissues express a number of antimicrobial peptides and
proteins that exert broad spectrum activity against fungi, bacteria,
and viruses such as HIV-1 [1–3]. Many are cationic in nature, and
owe their ability to prevent microbial and viral infections in part to
electrostatic interactions with membrane surfaces [4,5]. The
antimicrobial activity of human seminal plasma (SP) has been
established for decades [6,7]. Several reports have studied the
individual ubiquitous innate immune components present in SP,
including lactoferrin, lysozyme, HBD-1, and antimicrobial che-
mokines [8,9], as well as SP specific antimicrobial peptides,
including HE2a C-terminal fragments [10], and semenogelin-
derived peptides [11,12]. While the antibacterial properties of
seminal fluid have been established, only recently have the anti-
HIV-1 activities of human SP been described [13].
While human SP contains various antimicrobial factors, a
number of proviral factors have also been identified [14,15]. One
recent study has reported the ability of a natural proteolytic
fragment of the protein prostatic acid phosphatase (PAP
286;
residues 248–286) to form amyloid fibrils that are capable of
enhancing HIV-1 infection. Amyloid fibrils from the PAP-derived
peptide were generated in vitro through long periods of agitation,
and deemed Semen-derived Enhancer of VIrus (SEVI) [16].
Interestingly, the positive charge (pI=10.2) of SEVI reportedly
decreases the electrostatic repulsion between the negative charge
of the HIV virions and the negative overall charge of the target cell
membrane, leading to enhanced virion attachment [17].
Whole PAP is stored in the prostate, along with various other
enzymes and a large zinc ion reservoir that maintains prostate-
derived enzymes in an inactive state [18,19]. Upon ejaculation,
semen formsa gelatinous meshworkand issubsequentlyliquefied by
activated prostatic enzymes, principally the kallikrein-like serine
protease prostate-specific antigen (PSA) [20,21]. At neutral pH,
PAP reportedly exhibits amidolytic activity on semenogelins, the
major components of the seminal coagulum [22]. We have recently
reported that SP continues to degrade most of its intrinsic proteins
after liquefaction [13]; however, it has yet to be determined how
PAP undergoes cleavage into the PAP
286 fragments.
In the current study, we sought to elucidate the biological role of
PAP
286 with respect to its ability to form amyloid fibrils and
promote HIV-1 infection in the presence of human SP. While we
could confirm that PAP-derived amyloid fibril formation exhibited
HIV-1 enhancing activity, we found that this proviral activity was
neutralized by human SP. Moreover, SP retained significant anti-
HIV-1 activity in the presence of supra-physiological concentra-
tions of PAP amyloid fibrils. PAP peptides were degraded into
fragments that were not proviral within 3 h of incubation with
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enzymes, including prostate derived PSA and prostasin [20,23],
and epithelially derived matriptase [24]. Together, these results
confirm the ability of PAP-derived amyloid fibrils to enhance
HIV-1 infection alone; however, in the physiological milieu these
peptides and their resulting fibrils might be susceptible to
proteolytic degradation that could inhibit their proviral activity.
Materials and Methods
Ethics Statement
Samples of human semen were collected by the Center for
Reproductive Medicine as described previously [13]. As these
samples were discarded from routine testing, and not linked to any
identifiers, the University of Central Florida IRB has deemed them
exempt human subjects; therefore obtaining informed consent was
not applicable for this study.
Processing of human seminal plasma and PAP peptides
Semen was collected by the Center for Reproductive Medicine
as described previously [13]. Briefly, semen was collected from
patients who were asked to refrain from ejaculation for 2–5 days
prior. Semen was obtained via dry masturbation into a sterile
polypropylene cup, and allowed to liquefy for 30 min at room
temperature. A total of 103 individual seminal plasma (SP) samples
were centrifuged for 30 min at 15006 g, and the supernatants
were pooled and stored at 280uC or used for subsequent analyses.
An aliquot of the SP pool, referred to as ‘‘SP+(Ab)’’ hereafter, was
filtered through a sterile, nylon, 45 mm syringe filter (Fisher
Scientific, Pittsburgh, PA USA) and supplemented with 100 units/
ml penicillin, 100 mg/ml streptomycin, and 50 mg/ml gentamicin
as described previously [16]. An additional pool of eight semen
samples was collected, allowed to liquefy at room temperature for
30 min, and portioned into three fractions, ‘‘Pre-SP’’ (SP obtained
from semen prior to freezing at 220uC), ‘‘Post-SP’’ (SP obtained
from semen after freezing) and whole semen. All semen and SP
samples were then stored at 280uC until analyzed.
The synthetic PAP peptides corresponding to fragments PAP
248–266 (PAP
266) and PAP 248–286 (PAP
286) were synthesized as
previously described [16], via standard Fmoc solid phase
chemistry using a model 433A peptide synthesizer (Applied
Biosystems, Foster City, CA, USA). Crude peptides were purified
by preparative reversed-phase HPLC to .95% purity, and were
lyophilized. Masses were confirmed by MALDI-TOF MS. The
purified synthetic peptides were resuspended in sterile PBS and
stored at 220uC. To generate SEVI, peptides were agitated in a
thermomixer at 1400 rpm for 18 h at 37uC as described previously
[16]. For visual documentation, PAP peptides (1–5 mg/ml) with
or without SP (1%) were agitated in a thermomixer at 1400 rpm
for 36 h at 37uC to form observable amyloid fibrils as described in
[16,25], and were pulsed for 20 s at 10,000 rpm in a
microcentrifuge to sediment amyloid fibrils. Amyloid fibril
formation was monitored with Congo red staining as previously
described [25]. Fibril formation was measured at OD490nm using a
spectrophotometer. Stained fibrils were visualized using phase
contrast microscopy (Axiovert 200 M microscope, and Axiovision
4.5 software, Carl Zeiss MicroImaging, Inc., Thornwood, NY,
USA).
Cell lines and viruses
The HeLa-derived epithelia TZM-bl cell line and the
lymphocytic PM1 cell line were obtained from the National
Institutes of Health AIDS Research and Reference Reagent
Program (Germantown, MD, USA), and Peripheral Blood
Mononuclear Cells (PBMCs) were obtained from healthy donors
by AllCells, LLC (Emeryville, CA, USA). TZM-bl cells were
cultured in high glucose DMEM (Mediatech, Manassas, VA,
USA) supplemented with 100 units/ml penicillin, 100 mg/ml
streptomycin, and 10% (v/v) Fetal Bovine Serum (FBS) (Gemini
Bio-Products, West Sacramento, CA, USA). PM1 cell cultures
were maintained at a density of 0.4–0.8610
6 cells/ml in RPMI
1640 supplemented with 100 units/ml penicillin, 100 mg/ml
streptomycin, 10 mM HEPES, and 20% (v/v) FBS. PBMCs were
stimulated with phytohemagglutinin (PHA) (5 mg/ml) and 50
units/ml IL-2 for the first 3 days, and then maintained at a density
of 0.75–1.5610
6 cells/ml in R10 medium (RPMI 1640 with 10%
FBS) supplemented with 25 units/ml IL-2 (Roche Applied
Science, Indianapolis, IN, USA). HIV-1 BaL, an R5-tropic strain,
was obtained from the National Institutes of Health AIDS
Research and Reference Reagent Program (Germantown, MD,
USA). HIV-1 BaL was propagated in PM1 cells, and supernatant
was filtered and stored at -80uC until needed. Viral quantification
was achieved via a sensitive commercial ELISA for p24gag
(PerkinElmer, Waltham, MA, USA).
Antiviral and cytotoxicity assays
Antiviral assays were performed utilizing TZM-bl cells as
previously described [13]. Briefly, plated cells (6610
3 cells/well
incubated for 48 h, 4610
3 cells/well incubated for 24 h, or 8610
3
cells/well incubated for 24 h, 100 ml/well, 96 well plates) were
treated in triplicate. Original media was removed, and 50 ml
treatments were added to cells, which included vehicle only (PBS)
or a dilution of SP, semen, SEVI (agitated PAP
286), agitated
PAP
266, or a combination. Within 5 min of treatment being
supplemented, 50 ml of HIV-1 BaL (4 ng p24/ml or 200 pg p24/
well) or control media were added to cells. Cells were either
treated for 24 h, 3 d, or washed 3 h post-infection as previously
described [16].
A repeat of the methodology used to determine the effect of
seminal fluid on HIV-1 in infection [16] was carried out as follows.
TZM-bl cells were plated (1.4610
4 cells/ml incubated 24 h,
280 ml/well, 96 well plate), and treated in triplicate. 40 ml
treatments of SP diluted in PBS with or without SEVI or media
only controls were pre-incubated with 40 ml of HIV-1 BaL
(120 ng/ml or 4.8 ng p24) for 10 m at room temperature. Cells
were infected by adding 20 ml of the pre-incubated treatment to
the 280 ml of media, thus diluting the treatment and/or virus 15-
fold. After 3 h of incubation the treatment media was removed,
cells received 200 ml fresh media, and they were incubated for 3
days.
All treated cells were lysed using a Bright Glo luciferase system
(Promega, Madison, WI, USA), and the ability to prevent HIV-1
infection was measured as a percent reduction in luciferase
(relative light units or RLU) compared to the positive viral control
(media and virus only). Metabolic activity of the cells was verified
by a tetrazolium-based (MTT) assay according to manufacturer’s
instructions (R&D Systems, Minneapolis, MN, USA), while
cytotoxicity was measured using the standard trypan blue dye
exclusion assay.
PM1 cells (1.5610
5/0.1 ml) and PBMCs (5610
5/0.1 ml) were
treated with SEVI with or without SP, and infected with HIV-1
BaL (200 pg p24/0.1 ml) for 2 h. Cells were then washed, and
resuspended in fresh media with sample treatments for 5–7 days.
Supernatants were collected on alternate days, and cells in culture
were resuspended in sample or media alone. To ensure cell
viability, standard trypan blue dye exclusion assays were
performed. To quantify viral inhibition, the amount of p24gag
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Waltham, MA, USA).
PAP peptide incubations with SP and proteases
SP with or without a broad spectrum Protease Inhibitor (PI)
cocktail containing, 4-(2-aminoethyl)benzenesulfonyl fluoride
(AEBSF), pepstatin A, E-64, bestatin, leupeptin, and aprotinin
(Sigma) was incubated with PAP
286 or PAP
266 for 1–24 h at 300
rpm and 37uC. Serial dilutions of whole SP (1%–1:3200) were
incubated with PAP
286 for 24 h at 1400 rpm and 37uC. Semen
derived PSA and PAP were obtained from Sigma, trypsin was
obtained from Difco Laboratories (Detroit, MI, USA), and
prostasin and matriptase were produced as previously described
[26,27]. The proteases PSA, prostasin, trypsin, and matriptase
were diluted with sterile PBS to a final concentration of [1 mM]
and incubated with PAP
286 [54 mM] for 24 h at 300 rpm and
37uC. A series of PSA concentrations (1.5 mM–0.125 mM) were
incubated with PAP
286 (54 mM), and were agitated at 300 rpm for
24 h at 37uC. Whole PAP was resuspended in sterile PBS to
[10 mM]. 1% SP was incubated with PAP at a final concentration
of [2 mM] at 300 rpm and 37uC for timed intervals of 3, 6, 12 &
24 h. All incubation sample tubes were pulsed briefly in a
microcentrifuge, and immediately stored at 220uC. Samples were
electrophoresed on mini-16% Tricine-SDS gels, and stained.
Identification of protease cleavage products
Digested peptide fragments from protease incubations under-
went MALDI-TOF/TOF MS/MS analysis using the Model
Ultraflex III mass spectrometer (Bruker Daltonics, Billerica, MA,
USA) equipped with LIFT capability. Samples were desalted using
C18 ZipTips (Millipore, Bedford, MA, USA) and were analyzed in
positive reflector mode. External calibration was performed using
a mass standards kit for proteomics analyzer (Applied Biosystems).
Samples also underwent analysis via nano-LC ESI-TOF MS/MS
using the maXis ESI-Q-TOF (Bruker Daltonics) mass spectrom-
eter online with the Dionex model U3000 nanobore HPLC [28].
Data were analyzed with the Sprot database using the Bruker
ProteinScape program version 2.1 and Mascot program version
2.2 with enzyme setting to semiTrypsin.
Statistical analyses
The antiviral, metabolic, and cytotoxicity experiments were
performed at least three times, and each of the assays were
performed in triplicate or quadruplicate. For the TZM-bl antiviral
assays the infected vehicle-only controls were averaged and set as
100% infection. For the PM1 and PBMC antiviral assays, p24
ELISA quantification established the infected vehicle-only control
as 100% infection. Metabolic and cytotoxicity assays compared
results to the vehicle-only control, calculating variations as a
percentage of the baseline. Individual treatments were analyzed by
either one-way ANOVA with Tukey’s multiple comparisons post-
test or two-tailed unpaired t-test.
Results
PAP
286 amyloid fibril formation is inhibited by seminal
plasma
To confirm our synthetic PAP peptides would form detectable
amyloid fibrils in vitro, the PAP
286 and PAP
266 peptides were
agitated separately at either 1 mg/ml or 5 mg/ml according to the
established protocol for fibril formation [16]. Only agitated
PAP
286 (‘‘SEVI’’) generated turbid solutions and formed an
observable precipitate after centrifugation that was concentra-
tion-dependent (Figure 1A). In the presence of 1% SP (v/v),
generation of precipitate was either totally (1 mg/ml SEVI) or
partially (5 mg/ml SEVI) inhibited (Figures 1A). To visualize the
amyloid fibrils, samples were homogenized or stained with Congo
red, wet mounted on a slide, and viewed under phase contrast at
40x magnification. Several random field images were taken, and
SEVI alone (5 mg/ml) (Figures 1B & 1E) revealed numerous
fibrillar clusters, while the addition of 1% SP (Figures 1C & 1F)
substantially reduced fibril formation. The fibril formation
comparisons among SEVI, SEVI with 1% SP, and agitated
PAP
266 are demonstrated with the OD values from the Congo red
stained samples (Figure 1D). To confirm that SEVI fibrils
expressed HIV-1 enhancing activity, SEVI was added at various
concentrations to TZM-bl cells with R5 strain HIV-1 BaL for 24 h
(Figure 1G). SEVI demonstrated enhancement of HIV-1 in a
dose-dependent manner. To ensure cell viability, MTT assays
were run in parallel to the infection assays, and showed no adverse
effects to cell metabolism (Figure 1H). These studies confirmed
that our synthetic PAP peptides form active amyloid fibrils in vitro,
and that diluted human SP can inhibit amyloid fibril formation.
The HIV-1 enhancing activity of SEVI is inhibited by
seminal plasma
In order to determine if the HIV-1 enhancing activity of SEVI is
affected by SP, TZM-bl cells (plated at 6610
3 cells/well and
incubated for 48 h) were infected with HIV-1 BaL for 24 h in the
absence or presence of agitated PAP
286 (Figures 2A, C, E & G)
and agitated PAP
266 (Figures 2B, D, F & H). Note that since
fibrils formed only with PAP
286 peptides, but not PAP
266 peptides,
the term ‘‘SEVI’’ applies only to agitated PAP
286 peptides. In
specified conditions, whole SP was also agitated to determine if
SEVI fibrils would form and exhibit HIV-1 enhancing activity. SP
was utilized at a final concentration of 1% (v/v) to mitigate
cytotoxic effects. Treatments with SEVI (Figure 2A) and to a
lesser extent agitated PAP
266 (Figure 2B) revealed HIV-1
enhancing activity at physiological concentrations (35 mg/ml),
but these enhancing effects were negated when combined with
agitated or non-manipulated SP. We then repeated these antiviral
assays, but instead washed the cells with PBS and replaces with
media alone 3 h post-infection as reported in [16]. As shown in
Figures 2C & D, the trends remained as compared to the 24 h
treatment (Figures 2A & 2B). Moreover, we performed certain
experiments in the absence of FBS as reported in [16], which also
revealed that SP could reduce the proviral activity of SEVI and
PAP
286 (data not shown). To verify cell viability, MTT assays were
run in parallel to all antiviral assays, and revealed no significant
adverse effects to metabolic activity of cells treated for 24 h
(Figures 2E & 2F) or washed after 3 h (data not shown). For
further confirmation, trypan blue assays were also performed in
parallel to the infection assays at 24 h of treatment (Figures 2G
&2 H ) and revealed a lack of cytotoxicity.
In the results above, SP exhibited antiviral activity as previously
seen in our work [13], but in contrast to the results demonstrated
by others using subtle differences in methodology [16]. Therefore,
to determine if the difference in SP activity was influenced by
methodology of treatment, the methods used to determine the
effect of seminal fluid on HIV-1 infection were followed precisely
as described previously [16]. Minimally manipulated SP (0.4%,
2%, 10%) was tested in parallel with antibiotic supplemented and
filtered SP ‘‘SP+(Ab)’’, with or without SEVI, such that the final
concentrations of SP were (0.026%, 0.113%, 0.66%) (Figure S1).
While there was no significant reduction in metabolic activity, viral
infection was still inhibited by all treatments containing SP at the
final concentration of 0.66%, similar to the 1% final concentration
of SP used in the current manuscript and in our report [13]. Of
Seminal Plasma Reduces PAP Proviral Activity
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at every tested concentration, while filtered SP+(Ab) and filtered
SP+(Ab) containing SEVI both exhibited HIV-1 enhancing
activity. Importantly, these results suggest that viral enhancing
and inhibitory activities are concentration-dependent, and that the
process of filtration may interfere with certain antiviral compo-
nents of SP.
We next explored the effect of cell density and SP preparation
on antiviral activity. For a 24 h infection period (Figure S2), cells
seeded at 4610
3 cells/well and 8610
3 cells/well were treated with
either Pre-SP, Post-SP or Semen at 0.4%, 2%, or 10% (final
concentrations as in [16]), and infected with a final concentration
of 2 ng/ml HIV-1 BaL. The overall antiviral activity of the Pre-
SP, Post-SP, and Semen treatments exhibited similar trends
between the differing cell densities. However, when the same
experiment was extended to a 3 d infection period (Figure S3), as
performed in reference [29], a significant increase in cytotoxicity
was observed.
Figure 1. SEVI amyloid fibril formation is inhibited by SP. The synthetic PAP
286 peptide was agitated at concentrations of 1 mg/ml and 5 mg/
ml with or without whole SP (1%) for 36 h at 1400 rpm at 37uC. (A) Sample tubes were centrifuged briefly at 10,000 rpm, and each photographed at
the same angle. The 5 mg/ml samples without SP (B) and with SP (C) were vortexed briefly and 20 ml was wet mounted on a slide. (D) Agitated 5 mg/
ml PAP
266, 5 mg/ml SEVI, or SEVI+1% SP were stained with Congo red and measured at 490 nm with a spectrophotometer. Images of stained 5 mg/
ml SEVI without SP (E) or with 1% SP (F), were captured at 40x magnification with phase contrast filters under white light using the Axiovert 200 M
microscope and Axiovision 4.5 software. (G) TZM-bl cells (6610
3 cells/well incubated for 48 h) were treated with serial dilutions of SEVI and infected
with HIV-1 BaL (200 pg p24/well). Results are presented as a percent enhancement of viral infection compared to an infected, vehicle-only control. (H)
Identically treated cells were also subjected to MTT metabolic assays, presented as percent reduction in cellular metabolism when compared to cells
treated with vehicle alone. All presented experiments were performed at least 3 times, and error bars represent SEM.
doi:10.1371/journal.pone.0016285.g001
Seminal Plasma Reduces PAP Proviral Activity
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16285Seminal Plasma Reduces PAP Proviral Activity
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16285In order to validate our findings shown in Figure 2,i n f e c t i o n
assays were performed on PM1 cells (Figures 3A& 3C)andPBMCs
(Figures 3B & 3D) by measuring viral propagation over a multi-day
time course. Agitated PAP
266 and SEVI were added to cells at a final
concentration of 35 mg/ml with or without 1% SP. PBMC infections
confirmed HIV-1 enhancing activity of SEVI alone, whileboth assays
confirmed significant antiviral activity of SEVI spiked with SP. No
appreciablecytotoxicity tothe cellswas detected by trypanblue assays
(Figure 3C & 3D). Collectively, these results indicate that antiviral
activity of SP is retained in the presence of SEVI.
Seminal plasma naturally degrades PAP peptides over
time
We previously demonstrated that SP naturally degrades native
proteins over extended periods of time [13]. Since the proviral
activity of SEVI and agitated PAP
266 were significantly altered by
SP, we aimed to determine if PAP was susceptible to intrinsic
degradation. Whole PAP [2 mM] was incubated with 1% SP for
varying time periods at 300 rpm and 37uC, electrophoresed on a
Tricine-SDS polyacrylamide gel, and silver-stained (Figure S4).
The majority of the PAP protein was degraded within 12 h of
incubation, indicating the susceptibility of whole PAP to SP
proteases. Note that the PAP protein alone did not demonstrate
any observable self-cleavage (data not shown). Next, SP with or
without a protease inhibitor (PI) cocktail was incubated with either
PAP
286 (Figure 4A) or PAP
266 (Figure 4B) for set increments of
time at 300 rpm and 37uC. Tricine-SDS electrophoresis revealed
that PAP
286 and PAP
266 underwent partial degradation within
1 h, and complete degradation within 3 h. Samples containing the
PI exhibited preservation of the PAP peptides over time, indicating
that SP proteases were capable of degrading PAP.
Figure 2. Agitated PAP peptides do not significantly inhibit the anti-HIV-1 activity of SP. Whole SP, synthetic PAP
286, or synthetic PAP
266
were agitated at 37uC to promote fibril formation. TZM-bl cells (6610
3 cells/well incubated for 48 h) were then treated with either PBS, unagitated SP,
agitated SP, agitated PAP
286 (SEVI, Panel A), agitated PAP
266 (Panel B), or combinations of agitated peptides and SP, and infected with HIV-1 BaL
(200 pg p24/0.1 ml) for 24 h (A & B). SP preparations were administered at a final concentration of 1% (v/v) when diluted with cell media and virus.
PAP peptides were administered to cells at a final concentration of 35 mg/ml. (C & D) TZM-bl assays were performed as in A–B except that the cells
were washed 3 h post-infection. Results for A–D are presented as % inhibition or enhancement of viral infection compared to the cells infected in the
presence of PBS alone. Identically treated TZM-bl cells were also subjected to MTT metabolic assays (E & F) as described in Fig. 1, and trypan blue
cytotoxicity assays (G & H) in which % cytotoxicity was calculated from non-viable versus viable cell counts for each treatment condition. All
experiments were performed at least 3 times. Error bars represent SEM.
doi:10.1371/journal.pone.0016285.g002
Figure 3. Agitated PAP peptides do not significantly alter SP inhibition of HIV-1 release. (A) PM1 cells and (B) PBMCs were infected with
HIV-1 BaL (200 pg p24/0.1 ml) in the presence of whole SP (1%), SEVI, agitated PAP
266 (35 mg/ml), or SP (1%) and agitated PAP peptides (35 mg/ml)
combined, as well as a vehicle-only control. Five days (PM1 cells) and seven days (PBMC’s) post-infection, supernatant was collected to quantify p24
release by ELISA. Data are presented as a percent inhibition of infection in relation to the infected vehicle-only control. Treated PM1 cells (C) and
PBMCs (D) were also analyzed by trypan blue exclusion for assessment of cytotoxicity. All graphs represent, n=3.
doi:10.1371/journal.pone.0016285.g003
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concentration of SP necessary for PAP peptide degradation was
investigated. Serial dilutions of whole SP were incubated with
PAP
286 and samples were electrophoresed on Tricine-SDS
polyacrylamide gels, and stained with Coomassie (Figure 5A)
and then silver stain (Figure 5B). Partial degradation of PAP
286
occurred at dilutions of SP as high as 1:3200. Complete
degradation of PAP
286 was observed at 1:200 dilutions of SP,
and lower. These results indicate that SP contains fast-acting,
PAP-degrading proteases in excess.
Proteases within SP are capable of degrading PAP
286
Prediction of the protease cleavage sites (Expasy – peptidecutter)
revealed trypsin- and chymotrypsin-like cleavage sites within the
PAP
286 peptide, giving rise to the possibility of proteolytic
degradation of PAP
286 by these classes of proteases. In order to
determine the specific PAP-degrading proteases in SP, PAP
286 was
subjected to incubation with the SP proteases prostate-specific
antigen (PSA), prostasin, and matriptase, and with trypsin as a
positive control. PSA exhibits chymotrypsin-like activity, while
prostasin and matriptase exhibit trypsin-like activity. The samples
were electrophoresed using Tricine-SDS gels to reveal any
resulting cleavage products (Figure 6A). PSA and matriptase
treatments resulted in degradation of the PAP peptide with visible
cleavage products, while prostasin did not effectively degrade
PAP
286. Trypsin completely degraded the peptide, with no
cleavage products visualized. PAP
286 was incubated with serial
dilutions of PSA (Figure 6B), which demonstrated complete
PAP
286 degradation at 0.75 mM. This corresponded to a 1:72
molar ratio of PSA: PAP
286 necessary for complete cleavage. Note
that even the lowest concentrations of PSA tested (0.125 mM)
promoted partial PAP
286 degradation.
SP was analyzed in triplicate with a PSA-specific ELISA to
quantitate the intrinsic amount of this protease, which measured
311 mg/ml (11 mM) in whole SP, consistent with previous reports
[7,30]. Cleavage products from the protease incubations were
analyzed via MALDI TOF/TOF MS/MS and nano-LC-MS/MS
analysis. All proteases generated detectable cleavage products from
incubation with PAP
286 (Figure 7) with some overlap in cleavage
sites among the different proteases. Taken together, these results
demonstrate the ability of multiple SP proteases to cleave PAP
286
to various degrees, while the complete degradation of PAP
286 was
demonstrated by the most abundant SP protease, PSA.
Discussion
Our studies confirmed previous reports that SEVI alone was
capable of enhancing HIV-1 infection [16], and additionally
revealed that the native PAP
286 peptides and truncated forms
(PAP
266) were also proviral. This may suggest additional situations
in vivo in which PAP derived peptides could exert activity in the
absence of fully elongated amyloid fibrils. However, we also
revealed that proteolytic mechanisms within SP could reduce the
proviral effects of SEVI and PAP peptides under certain
conditions. Moreover, differences in treatment of SP and semen
Figure 4. PAP peptides undergo degradation by SP within hours. Purified PAP peptides were incubated with either whole SP, SP spiked with
a broad spectrum protease inhibitor (PI), or PBS, and incubated at 300 rpm, at 37uC, for the indicated durations. (A) Three volumes of PAP
286 (1 mg/
ml) were incubated with one volume of whole SP, and 2 ml of samples were added to gels. (B) PAP
266 (1 mg/ml) was similarly incubated with whole
SP, and 4 ml of samples were added to the gels. All samples were electrophoresed on Tricine-SDS-gels, and stained with Coomassie blue.
doi:10.1371/journal.pone.0016285.g004
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components that we have reported [13]. In vivo, both pro- and
antiviral situations could easily be explained by heretofore
unknown donor-to-donor differences in PAP peptide concentra-
tion, protease concentration, and other factors that might affect
the pro- and antiviral activity of SP directly or indirectly.
It is interesting to note that the ability of PAP-derived peptides
to form amyloid fibrils is a common characteristic for many
peptides and proteins given the correct conditions and time [31].
Fibril formation follows a model nucleation-dependent elongation
mechanism, initiated by a lag phase for nucleus seeding [32].
When tested at a concentration 57-fold higher than the 35 mg/ml
physiological concentration, SEVI exhibited a lag phase of ,10 h
[33]. Since concentration of the purified peptide plays a significant
role in fibril formation, the spontaneous formation of SEVI from
purified PAP
286 observed in previous studies may be a prime
example of this, due to supraphysiological stock concentrations (i.e.
10 mg/ml) used for fibril formation [16]. Without agitation, it was
found that fibril formation at lower concentrations of PAP
286 may
not occur or would require an exponentially longer lag phase time
[33]. Considering the lack of intense agitation post-ejaculation in
vivo and the significantly lower physiological concentration of
PAP
286, the lag phase of SEVI formation might afford ample time
for intrinsic inhibitors of SEVI to act.
As we observed, native proteases were responsible for the
degradation of whole PAP as well as PAP peptides in the presence
of SP. It is important to note that several protease incubation
studies we conducted contained a significant excess of PAP or PAP
peptides compared to SP or the protease of interest, suggesting
that catalytic amounts of proteases in SP are responsible for PAP
degradation in vitro. In addition, our SP samples contained greater
than a 100-fold excess of PSA than would be necessary to degrade
PAP
286. One conclusion might be that the physiological
concentration of SP would be sufficient to degrade PAP and
PAP peptides in vivo. Conversely, it is plausible that an unknown
promoter or stabilizer of SEVI formation might exist, which
induces the formation of fibrils more rapidly in vivo. Notably,
Figure 5. SP can degrade PAP
286. Freshly resuspended PAP
286
(1 mg/ml) was incubated with serial dilutions of whole SP at 1400 rpm
for 24 h at 37uC. Samples were electrophoresed on mini-Tricine-SDS-
gels, and visualized with Coomassie blue (A) and then silver stain (B).
doi:10.1371/journal.pone.0016285.g005
Figure 6. Proteases within SP degrade PAP
286. (A) PAP
286 (54 mM;
250 mg/ml) was incubated with various SP proteases (1 mM) at 300 rpm
for 24 h at 37uC. 3 ml of each sample were electrophoresed on Tricine-
SDS-gels, and silver stained. (B) The predominant SP protease PSA was
incubated with PAP
286 (54 mM) in serial molar dilutions. For each
sample, 3 ml were electrophoresed on mini-Tricine-SDS-gels, and silver
stained.
doi:10.1371/journal.pone.0016285.g006
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additional investigation, given that in vivo-formed SEVI fibrils
themselves have not yet been reported.
It must be noted that while PSA is the primary candidate for the
majority of PAP degradation, we also revealed other SP proteases
that could proteolyze PAP
286. Likewise, proteases in human
vaginal fluid, or mucosal proteases activated by the low pH in
vaginal fluid might also degrade PAP
286 or SEVI in the post-coital
environment [34]. While it is highly suggestive from our studies
that PAP and PAP peptide degradation can occur, the level to
which this occurs in vivo may vary widely and be one of several
reasons why the proviral effect has been reported to vary between
individuals [29].
In our study, we have assessed the pro- and antiviral activity of
PAP peptides and SEVI, under multiple conditions, many of
which reproduced methods and techniques utilized by other
groups [16,25,29]. In short, the various testing conditions all had
minor effects on the pro- and antiviral activities, yet the major
finding that SP can abrogate part or all of the in vitro proviral
activity of SEVI was still substantiated. Syringe-filtered SP could
confer HIV-1 enhancing activity under the right conditions,
perhaps due to the loss of cationic peptides and proteins as a result
of the filtration process. Both the concentration and duration of
treatment influenced the overall activity of SP. Variable cell
density led to differences in pro- and antiviral activity of SP and
semen, as well as differences in cytotoxicity. While methodological
Figure 7. Cleavage products of PAP
286, following incubation with SP proteases. The incubation products from the SP protease incubations
were analyzed via MALDI TOF/TOF MS/MS and nano-LC-MS/MS analysis. The cleavage products for each individual protease were marked under the
whole PAP
286 sequence. Underlined asparagine (N) residues could undergo deamidation, while methionine (M) residues marked with an asterisk (*)
could undergo oxidation.
doi:10.1371/journal.pone.0016285.g007
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research groups, it is unclear which more closely represents the in
vivo environment of HIV-1 infection.
Previous studies have demonstrated the broad spectrum
antimicrobial and antiviral activity of human seminal plasma
[12,13]. The heterosexual transmission of HIV is not efficient,
occurring as infrequently as 1 in every 1000 coital acts [35], which
might be rationalized in part by the observed antiviral activity of
human SP and the cationic antimicrobial and antiviral peptides
therein. Still, there are factors in SP that exhibit proviral activity in
vitro. PAP peptides have been confirmed in semen, and the extent
of their HIV-1 enhancing activity varies on an individual donor
basis [29]. Our current studies suggest that the formation and
activity of SEVI in vivo might be challenging in the presence of SP,
due to the natural degradation of PAP peptides by several intrinsic
proteases within SP. While to date there is a lack of evidence
confirming the ability of SEVI amyloid fibrils to form naturally in
non-manipulated human SP under physiological conditions in vivo,
it still remains possible that PAP peptides can generate fibrils in vivo
and exhibit HIV-1 enhancing activity under the right circum-
stances. Together, we anticipate that our findings will not only
spark intense discussion, but will unlock avenues for continued
research on the proviral and antiviral aspects of human SP.
Supporting Information
Figure S1 SP manipulation, as well as different infec-
tion methods, reveals a contrast in SP antiviral activi-
ty. TZM-bl cells were plated at 1.4610
4 cells/ml with 280 ml/
well, and incubated for 24 h. Treatments of 10%, 2% or 0.4% of
SP, or SP+(Ab) with or without SEVI (35 mg/ml) or media only
controls were pre-incubated with HIV-1 BaL (4.8 ng p24) for
10 min at room temperature. Cells were infected by diluting the
treatment and/or virus 15-fold in adding it to the cell media (final
0.66%, 0.113%, and 0.026% SP). After 3 h of incubation the
treatment media was removed, cells received fresh media, and they
were incubated for 3 d. Inhibition of viral infection is presented as
a percent reduction in luciferase activity compared to an infected,
vehicle-only control (A). Cells were also subject to MTT metabolic
assays (B), presented as the percent metabolic reduction as
compared to the negative control. For graphs, n=3; and error
bars represent SEM.
(TIF)
Figure S2 Infection of two cell densities for 24 h reveals
similar activity. TZM-bl cells seeded at 4610
3 cells/well
(A&B) and 8610
3 cells/well (C&D) were incubated for 24 h. Cells
were treated with a final concentration of 10%, 2% and 0.4% of
Pre-SP, Post-SP and semen, and then immediately infected with
the BaL laboratory strain of HIV-1 (200 pg p24) for 24 h. Due to
limited amount of sample, whole semen was not tested at 10%,
and deemed as Not Determined (ND). Inhibition of viral infection
was measured as a percent reduction in luciferase activity
compared to an infected, vehicle-only control (A&C). Cells were
subject to MTT metabolic assays (B&D), given as the percent
metabolic reduction as compared to the negative control. For
graphs, n=3; and error bars represent SEM.
(TIF)
Figure S3 Cell density influences the antiviral and
cytotoxicity of a 3 d infection. TZM-bl cells seeded at
4610
3 cells/well (A&B) and 8610
3 cells/well (C&D) were
incubated for 24 h. Cells were treated with a final concentration
of 10%, 2% and 0.4% of Pre-SP, Post-SP and semen, and then
immediately infected with the BaL laboratory strain of HIV-1
(200 pg p24) for 3 d. Due to limited amount of sample, whole
semen was not tested at 10%, and deemed as Not Determined
(ND). Inhibition of viral infection was measured as a percent
reduction in luciferase activity compared to an infected, vehicle-
only control (A&C). Cells were subject to MTT metabolic assays
(B&D), given as the percent metabolic reduction as compared to
the negative control. For graphs, n=3; and error bars represent
SEM.
(TIF)
Figure S4 Whole PAP is proteolytically degraded by SP
over time. Whole PAP protein [2 mM] was incubated with
whole SP diluted 1:100 at 300 rpm at 37uC for timed periods.
Sample tubes were immediately stored at 220uC when incuba-
tions times were ended. 4 ml of each sample were electrophoresed
on a mini-Tricine-SDS-gel, and silver stained.
(TIF)
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